Given that IFN-AABs are risk factors for a worse clinical outcome in hospitalized patients with COVID-19, future rapid identification of IFN-AAB-positive patients after hospital admission seems key for the potential implementation and success of specific interventions such as antivirals and/or monoclonal antibodies and/or TPE. The gene discussed is IFNA1; the disease is COVID-19.